ストックスクリーナーアプリを入手
298.48
1.42%
4.18
アフターアワーズ：
295.82
-2.66
-0.89%
前日終値:
$294.30
開ける：
$297.8
24時間の取引高:
800.50K
Relative Volume:
0.72
時価総額：
$39.85B
収益：
$4.29B
当期純損益:
$577.22M
株価収益率:
70.92
EPS:
4.2086
ネットキャッシュフロー:
$641.34M
1週間 パフォーマンス:
+2.40%
1か月 パフォーマンス:
-4.01%
6か月 パフォーマンス:
-33.04%
1年 パフォーマンス:
+2.33%
1日の値動き範囲:
$292.10
$300.08
1週間の範囲:
$284.38
$300.08
52週間の値動き範囲:
$284.19
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure - Investing.com
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
ALNY Technical Analysis & Stock Price Forecast - Intellectia AI
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
ALNY Initiated Coverage by Citigroup -- Price Target Set at $380 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Alnylam Issues 2025 Corporate Responsibility Report - BioSpace
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors - simplywall.st
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by iA Global Asset Management Inc. - MarketBeat
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Position Reduced by DNB Asset Management AS - MarketBeat
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by ANTIPODES PARTNERS Ltd - MarketBeat
Alnylam Pharmaceuticals Adjusts Valuation Grade Amid Strong Financial Performance Indicators - Markets Mojo
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750 - MSN
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20 - Stock Titan
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy? - Insider Monkey
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY) - Stock Titan
Capital Research holds 9.47M shares of Alnylam (NASDAQ: ALNY) in 13G/A - Stock Titan
Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth - AD HOC NEWS
5 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts - Insider Monkey
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - sharewise.com
ALNY: Strong AMVUTTRA growth, ambitious pipeline, and robust cash position drive future expansion - TradingView
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY) - Insider Monkey
Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data - AD HOC NEWS
Alnylam (ALNY) Reports Positive Phase 3 Results for Vutrisiran i - GuruFocus
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden - BioSpace
Heart drug vutrisiran tied to fewer deaths in ATTR-CM patients - Stock Titan
How Alnylam’s Swing to Quarterly Profitability Could Reshape the Outlook for Alnylam Pharmaceuticals (ALNY) Investors - simplywall.st
Behavioral Patterns of ALNY and Institutional Flows - Stock Traders Daily
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves - simplywall.st
Alnylam surges after its Pfizer-rivaling blockbuster jumps nearly 200% - MSN
Alnylam to Webcast Presentations at Upcoming Investor ConferencesMay 7, 2026 - BioSpace
Heart drug vutrisiran shows steady profile in new analyses - Longevity.Technology
FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up - Medical Marketing and Media
Porphyria Treatment Market to Reach USD 2.56 Billion by 2033 - openPR.com
Tenaya (NASDAQ: TNYA) trims R&D burn and signs Alnylam research pact - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) trims Q1 loss, lands Alnylam deal - Stock Titan
Alnylam Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
FMR LLC amends Schedule 13G to show 14.64M ALNY shares (NASDAQ: ALNY) - Stock Titan
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
3.95%
大文字化:
|
ボリューム (24 時間):